Podcasts about ALK

Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer. Presenters: Beth Sandy, MSN, CRNP, FAPO  Thoracic Oncology Nurse Practitioner Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Denise Rouse, MS, PA-C  Physician Assistant Thoracic Medical Oncology Department of Medicine, Section of Hematology/Oncology The University of Chicago Medicine & Biological Sciences Chicago, Illinois Link to full program: https://bit.ly/4rt1OCl Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

El Dr. Luis Antonio Lara Mejía, oncólogo médico del Instituto Nacional de Cancerología, en la Ciudad de México, participa en el Taller de Residentes de Oncología Médica RISE, 8.ª edición, donde aborda el cáncer de pulmón de células no pequeñas metastásico ALK positivo.Fecha de grabación: 16 de enero de 2026.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos, para uso personal, y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.El contenido, las opiniones y declaraciones presentadas son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.ScienceLink y los terceros mencionados no se responsabilizan por daños o consecuencias derivados del uso, interpretación o aplicación de la información, ni por errores u omisiones.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

Burnley chairman Alan Pace's comments about "three-year olds" and "temper tantrums" have inflamed passions among Burnley fans. Former Burnley FC PR manager Ed Abis joins Bodes, Simon and Greavesy to react to the 'car crash' Football Focus interview and discuss ALK's stewardship of the club in general. Will Pace make a decision over Scott Parker's future? How can the club better organise the football side to ensure improved performances and end the chaos around the team.

Este viernes, llega a las tablas del teatro Alkázar de Plasencia la obra 'El dilema del corcho', de Tartean Teatroa. En escena, Ramón Barea y Patxo Tellería en un thriller político que acaba convirtiéndose en una comedia. En el trasfondo, las donaciones de un multimillonario. Charlamos con Patxo sobre la función, los dilemas, el recorrido desde el estreno, en 2024, y un aniversario.

In this episode of 'Conversations in Lung Cancer Research,' hosted by Associate Professor Mal Itchens, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Professor Nick Pavlakis from Royal North Shore Hospital and Associate Professor Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the 2025 lung cancer screening program, anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. The episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices.00:00 Introduction to Lung Cancer Research Podcast00:37 Panel Introduction and Discussion Overview01:18 Lung Cancer Screening in Australia02:30 Impact of Screening on Diagnostic Services06:45 Screening Program Benefits and Challenges10:34 Future of Lung Cancer Screening15:54 Advancements in Diagnostic Technology20:57 Therapeutic Developments in Lung Cancer24:34 New Drug Listings and Their Impact40:04 Immunotherapy and Future Directions44:13 Conclusion and Final Thoughts  

In this podcast, Eric K. Singhi from the University of Texas MD Anderson Cancer Center, Houston, TX, USA, and Eric S. Nadler from the Baylor University Medical Center, Dallas, TX, USA discuss the available treatment options for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and focus on the efficacy and safety of first-line treatments and sequencing strategies. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-025-01192-y. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Wykład dr hab. Katarzyny Malinowskiej, prof. ALK w ramach Kawiarni Naukowej Festiwalu Nauki w Warszawie [12 stycznia 2026 r.]Eksploracja kosmosu to nie tylko misje na odległe planety – to realna inwestycja w bezpieczeństwo, gospodarkę i codzienne życie. Technologie satelitarne chronią nas przed zagrożeniami, wspierają obronność państw, a jednocześnie umożliwiają nawigację GPS, prognozę pogody i łączność internetową. Wykład pokaże, jak sektor kosmiczny generuje miejsca pracy, innowacje technologiczne i wzrost PKB, jednocześnie stawiając pytanie o koszty tych osiągnięć. Czy inwestycje w kosmos się opłacają?Zapraszamy do dyskusji!dr hab. Katarzyna Malinowska, prof ALK – doktor habilitowana nauk prawnych, radca prawny, profesor Akademii Leona Koźmińskiego. Ekspertka w zakresie prawa ubezpieczeń oraz prawa kosmicznego, z wieloletnim doświadczeniem doradczym dla rynku ubezpieczeniowego i reasekuracyjnego. Dyrektorka Centrum Studiów Kosmicznych ALK, kierowniczka studiów podyplomowych z zakresu przemysłu kosmicznego oraz ryzyka i ubezpieczeń majątkowych. Autorka licznych publikacji naukowych, prelegentka konferencji krajowych i międzynarodowych, zaangażowana w prace międzynarodowych organizacji eksperckich zajmujących się prawem ubezpieczeniowym i kosmicznym.Jeśli chcesz wspierać Wszechnicę w dalszym tworzeniu treści, organizowaniu kolejnych #rozmówWszechnicy, możesz:1. Zostać Patronem Wszechnicy FWW w serwisie https://patronite.pl/wszechnicafwwPrzez portal Patronite możesz wesprzeć tworzenie cyklu #rozmowyWszechnicy nie tylko dobrym słowem, ale i finansowo. Będąc Patronką/Patronem wpłacasz regularne, comiesięczne kwoty na konto Wszechnicy, a my dzięki Twojemu wsparciu możemy dalej rozwijać naszą działalność. W ramach podziękowania mamy dla Was drobne nagrody.2. Możesz wspierać nas, robiąc zakupy za pomocą serwisu Fanimani.pl - https://tiny.pl/d9wz-p96Jeżeli robisz zakupy w internecie, możesz nas bezpłatnie wspierać. Z każdego Twojego zakupu średnio 2,5% jego wartości trafi do Wszechnicy, jeśli zaczniesz korzystać z serwisu FaniMani.pl Ty nic nie dopłacasz!3. Możesz przekazać nam darowiznę na cele statutowe tradycyjnym przelewemDarowizny dla Fundacji Wspomagania Wsi można przekazywać na konto nr:33 1600 1462 1808 7033 4000 0001Fundacja Wspomagania WsiZnajdź nas: https://www.youtube.com/c/WszechnicaFWW/https://www.facebook.com/WszechnicaFWW1/https://anchor.fm/wszechnicaorgpl---historiahttps://anchor.fm/wszechnica-fww-naukahttps://wszechnica.org.pl/#kosmos #nauka #prawo #kawiarnianaukowa #satelity #bezpieczeństwo #gospodarka

Jessica Donington, MD, and Christine Bestvina, MD, join host Erin Gillaspie, MD, to unpack key lung cancer advances from ESMO 2025, including adjuvant ALK inhibition (ALINA, ELEVATE), perioperative immunotherapy (KEYNOTE-671), and the expanding neoadjuvant space in borderline resectable disease.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Daz is in the in the hotseat and joined by regular Pod Squad member Greavsey and former When The Ball Moves editor Martin Barnes to look at the Clarets 2-2 draw at home to Manchester United. The trio also discuss the FA Cup visit of Millwall, transfer window hopes and ALK's multi-club model...

Burnley head to Bournemouth on Saturday looking to end their run of seven straight losses and we preview the pre-Christmas game from all angles. Plus the latest on ALK and season ticket prices and more. 

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:  Introduction (0:00) Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32) Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59) Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53) Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41) Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39) Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44) Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16) Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14) Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19) Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04) Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07) CE information and select publications

In our new series called Perspectives on Lung Cancer, Dr. Paul Wheatley-Price sits down with two guests, both with a depth of experience in ALK+ lung cancer, which represents about 4-8% of all lung cancer cases in Canada. Dr. Cheryl Ho, medical oncologist at BC Cancer, provides her perspective as a physician treating these types of cancers in her daily practice, while Katie Hulan shares her journey as a patient diagnosed with ALK+ lung cancer in 2021, navigating the healthcare system, and her path to launching ALK Positive Canada to advocate for better awareness of this subtype of lung cancer.

This week's episode is one I'll carry with me for a long, long time.Marina joined me to talk about a different kind of grief - the grief that comes before loss. The kind that lives inside uncertainty, scans, treatments, watching your child grow, and holding both hope and heartbreak in the same breath.At 34, Marina was living her dream life in the west of Ireland - painting, teaching, growing a garden, building a future with her husband. Then came a diagnosis that changed everything: ALK-positive lung cancer. A disease she never imagined could happen to her, and one that is, for now, incurable.In this conversation, Marina speaks with honesty, clarity and unbelievable strength about: • the shock of diagnosis • the years of treatment that followed • becoming a mother after cancer • parenting through uncertainty • anticipatory grief • the everyday beauty she holds onto • and the spiritual grounding that keeps her goingI'm so grateful Marina trusted this space with her story. It's emotional, it's human, it's real, and it will stay with you.If you or someone you love is navigating cancer, or the uncertainty of life-limiting illness, there is support, community, and advocacy happening every single day. I've linked to Marina's work and the Marie Keating Foundation below.Where to Find MarinaInstagram: https://www.instagram.com/marinawild_art/Website & Artwork: https://www.marinawild.com/Marie Keating FoundationSupport, information & resources: https://www.mariekeating.ieLung cancer awareness & advocacy: https://www.mariekeating.ie/cancer-information/lung-cancer/ Hosted on Acast. See acast.com/privacy for more information.

This week, MacB joins us in the PDH Pod studios as we build some decks using commander only ever printed in Universes Beyond products. There is a surprisingly large number of potential commanders out there for Pauper Commander. SocialsSupport the show HEREEmail the show HEREFollow the show HERECheck out Alk's SMBS streams HERE

Heute wird's freizügig an den Mikros, denn es kommt ein Mann zu Gast an die Mikros, der das Adamskostüm zu tragen weiss wie kein zweiter. Mario Holubek spielt freischwingend bei der Deutschen Nacktionalmannschaft vor Publikum wo gepöhlt wird wie zu besten Hugh Hefner Zeiten. Und am liebsten wenn es warm ist, sie wissen schon. Das Wort „Lattenknaller“ bekommt heute ne ganz neue Bedeutung. Mario trägt den Ruhrpott im Gesicht und war damals wohl der einzige 12 Jährige, der schon als Kind Kippen und Alk anne Bude bekommen hat. Seine Seele ist blau-weiss und mit der Nummer 69 setzt er auf den Fussballplätzen der Nation eine ganz klare Marke. Warum er das macht? Das erzählt er uns heute. Willkommen im Bottcast und in Folge 247.

Today, things begin to grow in the rice pudding. Mr. Rushworth has the hots for landscaping, Molly gets bitchcrackers for Miss Crawford, and the tides turn on our affections for Edmund when he lends out Fanny's mare. Topics discussed include hear me out cakes, apricots, Mary Crawford's poor breeding, what values we take from our families, Jane Austen's beautiful descriptions of love and how we're getting it in a different way in this book, regifting, Fanny as a chronically ill and/or anxious girlie, and pug the basset hound.Patron Study Questions this week come from Ghenet, Avi, Spring, Diana L., Angelika, Katie, Linnea, Marija, and Melissa. Topics discussed include POV shifting, landscaping and architecture, chronic illness in Austen, Edmund's manipulation of Fanny, Fanny's relationship to the servants, the number of monologues in this book, Edmund being more like his family than we thought, and all things Mary Crawford.Becca's Study Questions: Topics discussed include Edmund and Fanny's conversation about Mary and the romance brewing between Edmund and Mary.Funniest Quote: “The tree thrives well beyond a doubt, madam. The soil is good, and I never pass it without regretting that the fruit should be so little worth the trouble of gathering.”Questions moving forward: If not her cousin, then whomst?Who wins the chapters? The horse

Mañana 16 de noviembre celebramos el Día Mundial del Flamenco coincidiendo con la Declaración del Flamenco como Patrimonio Inmaterial de la Humanidad por la UNESCO. Y por eso en este programa reflexionamos sobre este arte con la Peña más antigua de Extremadura, La Asociación de Arte Flamenco de Badajoz, concretamente con su presidente Manuel Iglesias. Charlamos de la situación tan complicada en la que se encuentran las peñas y de la esencia de este ARTE que tenemos que seguir preservando. También les hablamos del Festival Flamenco de Cáceres que cumple 51 años con mucha salud e ilusión como nos contará su organizador Pepe Chaves, presidente de la Asociación Amigos del Flamenco de Extremadura. Y hablamos con uno de los artistas que estará en este festival de Cáceres, el extremeño Daniel Castro que no para de cosechar éxitos en los concursos de cante nacionales a los que se presenta. Además les traigo un resumen de nuestra visita a Plasencia. Estuvimos en la comida de hermadad de la Peña Flamenca Virgen del Puerto, dirigida por Román Hernández. Y les recuerdo que esta tarde a las 8 en el teatro Alkázar de Plasencia será la Peña Flamenca Placentina la que celebre su festival flamenco de Otoño "García Matos". Repasamos el resto de citas flamencas que tenemos estos días en Extremadura, que no son pocas. Y nos despedimos con el cante del Maestro Fosforito que falleció este jueves a las 93 años. Descanse en Paz. Con Laura Zahínos.

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

Dans ce nouvel épisode et en ce mois de sensibilisation au cancer du poumon, Mélanie et Ginger reçoivent Manon.Manon a appris il y a un peu plus d'un an qu'elle est atteinte d'un cancer du poumon ALK+ , dit « le cancer du non-fumeur ».Manon est aussi active dans l'association ALK France Cancer Poumon https://alkros1france.com/ créée en 2021, qui regroupe patients, aidants et professionnels concernés par les cancers du poumon à mutation rare (ALK et ROS1). Elle informe et accompagne environ 400 patients, soutient la recherche et organise une collecte de fond de 105 000€.Un essai clinique innovant, baptisé EspoirALK, est prêt à démarrer à l'Institut Gustave Roussy, particulièrement prometteur pour un tiers des patients ALK. Soutenu par des experts mondiaux (Pr Besse, Dr Shaw, Pr Barlesi), cet essai pourrait redonner de l'espoir à des patients en impasse thérapeutique.Pour aider la recherche, et soutenir le lancement de cet essai clinique une cagnotte est lancée > https://www.helloasso.com/associations/alk-france-cancer-poumon/collectes/espoir-alk-1-essai-clinique-pour-la-vie Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Warum gehen viele Männer erst zum Arzt, wenn sie Blut spucken? Viele halten ihre Gesundheit für selbstverständlich – bis der Körper streikt.Peter Großmann, TV-Moderator und selbst über 60, zeigt Dir die 5 Hebel, mit denen Du fit bleibst – ohne Dein ganzes Leben der Fitness unterzuordnen. Du erfährst, wie Du dranbleibst, auch wenn die Couch ruft, der Stress steigt und die Zeit knapp ist.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.____________Du kennst ihn vielleicht aus dem ARD-Morgenmagazin – Peter Großmann, das Gesicht des Sports im deutschen Fernsehen. Aber was ihn für dieses Gespräch besonders wertvoll macht: Er hat selbst die 60 geknackt und weiß aus eigener Erfahrung, wovon er spricht.Genau das macht ihn so glaubwürdig, wenn er über Männergesundheit spricht. Über das Bauchfett, das plötzlich bleibt. Über Muskelmasse, die schwindet, und Testosteron, das im Laufe der Zeit weniger wird. Und über die vielen kleinen Ausreden, mit denen wir Männer uns häufig selbst sabotieren, ohne es überhaupt zu merken, und um die wir uns oft erst kümmern, wenn es schon zu spät ist.

On this week's episode, Josh and Michael exchange the established treatment landscape of EGFR and ALK mutant NSCLC for the developing management of disease harbouring KRAS and MET mutations. The most common mutation meets one of the least common in this battle of therapeutic tenacity.Studies discussed in this episode:INSIGHT-2KRYSTAL-12For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? You'll just have to listen and find out.Studies discussed in this episode:MARIPOSACROWNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Join us in this episode of the Oncology Brothers podcast as we dive into the highlights from the World Conference on Lung Cancer 2025! We are joined by Dr. Balazs Halmos, a thoracic medical oncologist at the Montefiore Einstein Cancer Center, to discuss three pivotal studies that are shaping the future of lung cancer treatment. In this episode, we covered: •⁠  ⁠FLAURA2 Trial: Discover the significant overall survival benefits of combining osimertinib with chemotherapy for patients with EGFR-positive non-small cell lung cancer, and how it compares to single-agent osimertinib. •⁠  ⁠HARMONi Trial: Explore the intriguing yet complex findings of a new bi-specific antibody targeting PD-1 and VEGF in patients with progressive EGFR-mutated disease, and the implications of its current negative results. •⁠  ⁠ALCHEMIST Trial: Learn about the role of crizotinib in the adjuvant setting for ALK-positive lung cancer and why it reinforces alectinib as the standard of care. Tune in for an insightful discussion on the latest advancements in precision medicine, the importance of ctDNA, and the evolving landscape of lung cancer treatment.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Are you up to date with therapy strategies for ALK translocation and EGFR mutation–positive non-small cell lung cancer? Credit available for this activity expires: 9/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002896?ecd=bdc_podcast_libsyn_mscpedu

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Ken Culver, MD, the director of Research and Clinical Affairs at ALK Positive Inc.  Drs Camidge and Culver discussed the highlights of Dr Culver's career, which has been shaped by clinical practice, research, industry leadership, and patient advocacy. They noted elements of ALK Positive that set it apart from other patient advocacy groups, including its being entirely created, funded, and led by patients with stage IV lung cancer and their caregivers. Culver explained how he collaborates with patients to expand treatment opportunities, meets with companies and universities worldwide, and helps stakeholders recognize both the unmet needs and financial incentives for developing therapies for ALK-positive lung cancer. Culver detailed his path to the oncology field, which began with an intention to practice as a community pediatrician in Iowa. This led him to pursue residency training in California, where he gained diverse clinical experience, particularly in HIV/AIDS at the height of the epidemic. His early research explored HIV transmission in children born to drug-using mothers, highlighting the immunosuppressive effect of drug abuse even in the absence of HIV. During his fellowship, he contributed to pioneering work in gene therapy. He also participated in research that laid the groundwork for tumor-directed therapies, which later influenced large-scale clinical trials. Eventually, Culver explained that transitioned to industry. At Novartis, he contributed to the development of important drugs and witnessed the transformative launch of imatinib (Gleevec), one of the first targeted cancer therapies. Alongside his professional work, Culver established the Foundation for Peace, a nonprofit providing medical and community support in the Dominican Republic, Haiti, and Kenya. This initiative, which began with a mission trip in 1989, has grown to involve hundreds of volunteers annually, offering both medical care and broader community services. In his current role with ALK Positive, Culver noted that he has leveraged patient-led advocacy to influence industry priorities, resulting in several new clinical trials for ALK-positive patients. His work emphasizes balancing discovery research with near-term clinical opportunities to directly benefit patients with cancer today. He also shared how he prioritizes tools to empower patients, such as clinical trial finders, and stressed the importance of having contingency plans before disease progression. Overall, this conversation highlights a career that reflects a consistent commitment to science, patient care, and global service, guided by both professional and humanitarian values.

Czy odpowiedzialny biznes to oksymoron? Czy firma, która w swoich strategiach uwzględnia ESG (wpływ na środowisko, społeczeństwo i sposób zarządzania w kontekście zrównoważonego rozwoju) to "frajer biznesu"? Czy unijne "regulacyjne tsunami", które miało wymuszać proces dekarbonizacji, ochronę bioróżnorodności i zamknięcie obiegu materiałów okaże się jedynie "regulacyjną mżawką"? Zapraszam na rozmowę z prof. dr hab. Bolesławem Rokiem, który kieruje Centrum Badań Przedsiębiorczości Pozytywnego Wpływu w ALK oraz studiami podyplomowymi „Perspektywa ESG. Odpowiedzialne i zrównoważone zarządzanie”. Jest też współautorem Rankingu Odpowiedzialnych Firm i Startupów Pozytywnego Wpływu, współtwórcą programu Climate Leadership powered by UN Environment i uczestnikiem licznych projektów z zakresu neutralności klimatycznej biznesu, GOZ i ESG.Jeśli doceniasz moje treści, rozważ proszę wsparcie tego kanału:Postaw mi kawę na https://buycoffee.to/odpowiedzialnamoda Dołącz do Patronite: https://patronite.pl/odpowiedzialnamodaKup moją książkę "Odpowiedzialna moda" (wydawnictwo Znak) - dostępną także jako e-book i audiobook. Instagram: @odpowiedzialnamodaPodcastu Odpowiedzialna Moda można słuchać także w aplikacjach: m.in. na Spotify, Apple Podcasts, Anchor i EmpikGo.

Urvashi Prasad has spent the last 15 years trying to make the world a kinder, fairer, and better place through her policy-based interventions in heathcare. Armed with degrees from Cambridge and LSTH, she worked as a director at NITI Aayog, and was awarded the India-UK Achievers Award. In addition to sharing principles and frameworks for building meaningful careers in public policy, Urvashi opens up about losing her beloved father and being diagnosed with cancer soon after. We admire her resilience and are proud to share her story with you. Here you will learnHow governments attempt to address systemic challenges in sectors like healthcareHow young professionals can carve out interesting and impactful careers in public policy How to make sense of life when you lose your beloved parent and are diagnosed with cancerUrvashi Prasad is a public health and policy advisor with over 15 years of leadership across government, academia, and grassroots innovation. As Director in the Office of the Vice Chairperson at NITI Aayog, India's apex policy think tank, she helped shape the country's COVID-19 response strategy, monitor Sustainable Development Goals in real time, and spearhead national programs advancing public health, gender equity, and social inclusion.A co-author of India's first Voluntary National Review presented at the UN High-Level Political Forum in 2017, Urvashi's policy insights have been featured in 150+ publications globally. She is also the British Council's UK Alumni Ambassador for SDG 10, an Honorary Professor at De Montfort University, UK, and a member of the World Economic Forum's Expert Network. Her accolades include the India-UK Achievers Honors and recognition among India's most influential women. In 2023, she founded Spcace by Urvashi, a pioneering platform amplifying patient voices.Diagnosed with Stage 4 ALK-positive lung cancer at age 35, Urvashi now brings lived experience to the policy table --challenging invisibility in cancer discourse and driving recognition of under-researched malignancies in young adults. Her advocacy bridges science, storytelling, and systemic reform.She holds a master's in public health from the London School of Hygiene & Tropical Medicine, an MPhil in Bioscience Enterprise from Cambridge University, and a Bachelor's in Biological Sciences (Genetics) from the University of Birmingham, UK. In 2024, Urvashi received an honorary doctorate for her work in public health and policy.

This is an edited version of an interview that first appeared in episode 79 in September 2020. Ian Duff worked as a keeper at 13 Scottish lighthouses between 1976 and 1992. He spent about five years at Skerryvore, a remote station off the west coast of Scotland. He also spent about five years at Duncansby Head Light Station at the most northeasterly point of the British mainland. Ian Duff at St. Abbs Head Lighthouse in Scotland. Photo by Jeremy D'Entremont. Ian remained involved with lighthouses after his retirement as a keeper. He became the president of the Association of Lighthouse Keepers, or the ALK, an organization that provides a forum for everyone interested in lighthouses, lightships, and maritime aids to navigation. When Ian passed away last year, a large collection of his photographic slides were donated to the Museum of Scottish Lighthouses, along with lighthouse artifacts. Skerryvore Lighthouse (U.S. Lighthouse Society)

Notas del Show: En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street se mantiene plano ante foco en aranceles: Futuros sin dirección clara: $SPX y $US100 sin cambios, $INDU -0.2 %. El mercado sigue digiriendo las cartas de tarifas de Trump y el impacto político. Hoy se publican solicitudes de desempleo (consenso: 245K). • Delta sorprende y eleva previsión anual: $DAL sube +10 % premarket tras superar estimaciones del 2T con buenos márgenes en servicios premium y fidelidad. También suben $AAL, $UAL, $LUV, $JBLU y $ALK entre +2 % y +7 %. • MP Materials se dispara con apoyo del Pentágono: $MP +38.9 % tras anunciar una nueva planta de imanes y expansión en Mountain Pass con respaldo multimillonario del Departamento de Defensa. Refuerza independencia de EE.UU. frente a tierras raras extranjeras. • Palantir eleva guía y apunta a liderazgo AI: $PLTR mantiene rating Outperform en Wedbush, que sube su precio objetivo a $160. Destacan su potencial para superar los $1B en ingresos por IA y su papel clave en EE.UU. y la OTAN. • OpenAI desafía a Google con navegador AI: OpenAI, respaldada por $MSFT, lanzará un navegador conversacional para competir con Chrome y redirigir el uso de la web a través de IA. Busca integrar ChatGPT en la experiencia diaria y captar cuota publicitaria. Una jornada con foco en innovación, defensa estratégica y tecnología disruptiva. ¡No te lo pierdas!

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics: Introduction: Actionable Genomic Alterations (0:00) ALK (9:49) ROS1 (22:22) HER2 (31:00) RET (38:52) NTRK (45:30) MET (46:31) Novel Targeted Strategies (49:09) BRAF (54:19) KRAS G12C (55:38) CME information and select publications

Vi har med oss legen Oscar Ohene Asante, Øre-nese-hals-spesialisten – og ikke minst en dedikert løper selv!Lyse morgener, grønne parker og nye treningsmuligheter lokker oss ut i det fri. Men for en pollenallergiker kan denne tiden på året kjennes mer som en kamp enn nytelse. Trøtthet, kløende øyne og rennende nese er ikke akkurat drømmeselskap på trening – så hvordan holder man koken uten at allergien får overtaket?I denne episoden av Treningspodden får du svaret! Oscar forklarer hva pollenallergi egentlig er, hvilke symptomer som er de vanligste – og viktigst av alt: hvordan du kan lindre plagene. God lytt! Denne episoden er laget i samarbeid med ALK – et globalt, forskningsdrevet selskap som jobber med forebygging, diagnostisering og behandling av allergi. ALK står også bak nettsiden pollenkontroll.no, hvor du finner nyttig informasjon og verktøy for å få bedre kontroll på hverdagen med pollenallergi. Hosted on Acast. See acast.com/privacy for more information.

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital. In this episode, we covered: •⁠  ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations. •⁠  ⁠The importance of comprehensive NGS testing and the need for retesting at progression. •⁠  ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities. •⁠  ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies. •⁠  ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. YouTube: https://youtu.be/LMYDAjZcn5w Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

A Biomarker Dialogue Between Patient and Scientist HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Marc Muskavitch, PhD, ALK+ & Zachary Rogers, PhD, Research Fellow, Koch Institute at MIT This episode features a powerful conversation between two scientists, one now navigating life as a Stage 4 ALK+ lung cancer patient. Most lung cancer patients only learn … Continue reading Living with ALK+: Diagnosis, Treatment, & Hope →

Fuld gang i rapporteringen fra de danske selskaber tirsdag, der bringer nyt fra Vestas, ISS, Coloplast, ALK, DFDS og - sidst på dagen - Demant. Millionærklubben tjekker stemningen og tager desuden en tur forbi oliepriserne, der efter sidste nyt fra OPEC+ viger i pris. I studiet: Lau Svenssen og Bodil Johanne Gantzel.See omnystudio.com/listener for privacy information.

Hvordan vet du om barnet ditt har pollenallergi – eller om det bare er en lang vårforkjølelse? Hva er første steg i behandling, og hva kan du gjøre i hverdagen for å lindre plagene?Barnelege og allergiforsker Tonje Reier-Nilsen forklarer hvordan pollenallergi kan påvirke barnets livskvalitet – og hvorfor tidlig diagnose og riktig behandling kan gjøre en stor forskjell.Episoden er laget i samarbeid med ALK, et forskningsdrevet legemiddelselskap som jobber med forebygging, diagnostisering og behandling av allergi – og driver nettsiden www.pollenkontroll.no. Hosted on Acast. See acast.com/privacy for more information.

Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode,  Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives.   Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.  

This PER® Spectives™ featured podcast reviews the 22nd Annual Winter Lung Cancer Conference® held in January/February 2025. Multiple successive generations of ALK inhibitors have provided increasing benefits as first-line treatment for the thousands of patients with non-small cell lung cancer (NSCLC) that harbors rearrangements or mutations in the ALK gene. This program focuses on the practical aspects of managing patients with ALK-positive advanced or metastatic NSCLC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications

Are you up to date on the most optimal management of patients with early-stage ALK-positive non-small cell lung cancer (NSCLC)? Credit available for this activity expires: 3/24/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/preeclampsia-biomarker-screening-every-trimester-2025a100065r?ecd=bdc_podcast_libsyn_mscpedu

In today's episode, supported by Summit Therapeutics, we had the pleasure of speaking with Xiuning Le, MD, PhD, about the use of ivonescimab (SMT112) in patients with PD-L1–positive non–small cell lung cancer (NSCLC). Dr Le is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston. The phase 3 HARMONi-2 trial (NCT05499390) investigated ivonescimab vs pembrolizumab (Keytruda) in patients with locally advanced or metastatic, PD-L1–positive NSCLC without sensitizing EGFR mutations or ALK translocations. At the preplanned interim analysis, at a median follow-up of 8.7 months (IQR, 7.1-10.3), the median progression-free survival was significantly longer in the ivonescimab arm (n = 198) vs the pembrolizumab arm (n = 200), at 11.1 months (95% CI, 7.3-not estimable) vs 5.8 months (95% CI, 5.0-8.2), respectively (stratified HR, 0.51; 95% CI, 0.38-0.69; 1-sided P < .0001). The objective response rates were 50% (95% CI, 43%-57%) and 39% (95% CI, 32%-46%) in these respective arms. In our exclusive interview, Dr Le discussed the rationale for the HARMONi-2 trial, key findings from the study, and where these findings position the potential role of ivonescimab in the PD-L1–positive NSCLC treatment paradigm.

Tracey Ryniec, Zacks Value Stock Strategist, looks for stocks with high Zacks Rank and low PEG ratios. (0:30) - Can The PEG Ratio Help You Find Strong Value Stocks For Your Portfolio? (4:20) - Tracey's Top Stock Picks To Keep On Your Watchlist Right Now (24:30) - Episode Roundup: UAL, COOP, FOLD, ALK, AAL

Tracey Ryniec, Zacks Value Stock Strategist, looks for stocks with high Zacks Rank and low PEG ratios. (0:30) - Can The PEG Ratio Help You Find Strong Value Stocks For Your Portfolio? (4:20) - Tracey's Top Stock Picks To Keep On Your Watchlist Right Now (24:30) - Episode Roundup: UAL, COOP, FOLD, ALK, AAL Podcast@Zacks.com

308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD) She is a top insider with the Andreas Kalcker Institute, his ALK foundation, and their international umbrella organization, COMUSAV. Support the show Writer | Robert Yoho author

308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD) She is a top insider with the Andreas Kalcker Institute, his ALK foundation, and their international umbrella organization, COMUSAV. Support the show Writer | Robert Yoho author

S&P Futures are trading slightly lower this morning due to weakness in semiconductors. Markets are questioning the numbers and the timing of the recently announced Stargate Project. Key event today will be President Trump's speech today at Davos summit. Trump is schedule to speat at 11:00 am ET. His interview last night was rather uneventful as the focus was on his issues with former president Biden and FEMA. Central Bank meetings are on watch, the BOJ will make an announcement tomorrow, FOMC announcement on Jan 29th, and the ECB announcement is scheduled for Jan 30th. Earnings beats came in from ALK, DFS, GE, and MKC. After the bell today TXN and ISRG will report, and tomorrow morning AXP & VZ will report. European shares are mixed to higher & oil prices are higher by +0.50% this morning.